Undersea and Hyperbaric Medical Society

RestorixHealth Welcomes Dr. William H. Tettelbach as New Chief Medical Officer

Retrieved on: 
星期四, 七月 13, 2023
Research, Nursing, Surgery, Medical Supplies, Hospitals, Other Health, Managed Care, General Health, Health, Science, Newton, CWSP, Duke University, Medical Affairs Bureau, Intermountain Health, Monika Boehm-Tettelbach, Western University, FACP, Quality of life, Undersea and Hyperbaric Medical Society, Health informatics, MiMedx, Multimedia, Infection, CMO, 13th Waffen Mountain Division of the SS Handschar (1st Croatian), JWC, FIDSA, Medical director, MD, Patient, Outline of health sciences, Internal medicine, Mountain Division, HCA Healthcare, Hyperbaric medicine, Wound healing, Hospital, Podiatry

RestorixHealth, the nation’s leading wound care solutions company, has announced that Dr. William H. Tettelbach, MD, FACP, FIDSA, FUHM, MAPWCA, CWSP has been named Chief Medical Officer (CMO).

Key Points: 
  • RestorixHealth, the nation’s leading wound care solutions company, has announced that Dr. William H. Tettelbach, MD, FACP, FIDSA, FUHM, MAPWCA, CWSP has been named Chief Medical Officer (CMO).
  • He comes to RestorixHealth from HCA Healthcare, where he served as the Executive Medical Director, Wound & Hyperbaric Medicine Services for the Mountain Division.
  • View the full release here: https://www.businesswire.com/news/home/20230713335918/en/
    Dr. William H. Tettelbach, MD, FACP, FIDSA, FUHM, MAPWCA, CWSP has been named Chief Medical Officer (CMO) of RestorixHealth.
  • Dr. Tettelbach lends his expertise to numerous professional societies, committees and associations and has co-authored numerous research articles and book chapters.

CūtisCare Launches Third Annual Hyperbaric Aware™ National Campaign To Elevate Awareness Of Hyperbaric Oxygen Therapy

Retrieved on: 
星期一, 五月 1, 2023
Osteoradionecrosis, Medicine, Undersea and Hyperbaric Medical Society, Diabetes, Amputation, HBOT, Necrotizing fasciitis, Underwater environment, BOCA, Quality of life, Research, Gangrene, Hyperbaric medicine, Patient, Physician, Center of excellence, Actinomycosis, Pharmaceutical industry, Hospital

BOCA RATON, Fla., May 1, 2023 /PRNewswire/ -- Hyperbaric Awareness USA™, a CutisCare initiative, has designated May Hyperbaric Awareness Month and is proud to announce the launch of the third annual Hyperbaric Aware™ national campaign to elevate awareness of hyperbaric oxygen therapy (HBOT).

Key Points: 
  • BOCA RATON, Fla., May 1, 2023 /PRNewswire/ -- Hyperbaric Awareness USA™, a CutisCare initiative, has designated May Hyperbaric Awareness Month and is proud to announce the launch of the third annual Hyperbaric Aware™ national campaign to elevate awareness of hyperbaric oxygen therapy (HBOT).
  • CutisCare launches a Hyperbaric Awareness USA campaign to elevate the awareness of hyperbaric oxygen therapy.
  • (HBOT)
    The Hyperbaric Aware website, HyperbaricAware.com , in collaboration with the Undersea and Hyperbaric Medical Society (UHMS) and physician leaders, has resources available for both patients and physicians alike.
  • Help us spread the word this May about the many benefits of Hyperbaric Oxygen Treatment!

Diffusion Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
星期四, 五月 12, 2022
Risk, Company, Radiation, Private Securities Litigation Reform Act, Regulation of tobacco by the U.S. Food and Drug Administration, Research, Food, U.S. Securities and Exchange Commission, Hypoxia, 2021 Essex County Council election, Patient, NASDAQ, COVID-19, Particular, Trial of the century, Annual report, Hope, Industry, Compliance, Program, Coronavirus Scientific Advisory Board (Turkey), Oxygen, Security, Underwater environment, SAB, TSC, Undersea and Hyperbaric Medical Society, Tissue, GLOBE, Pharmaceutical industry, Diffusion

Continued Enrollment in TSC ILD-DLCO Trial: Diffusion announced dosing of the first patients in December 2021 and enrollment continued during the first quarter of 2022.

Key Points: 
  • Continued Enrollment in TSC ILD-DLCO Trial: Diffusion announced dosing of the first patients in December 2021 and enrollment continued during the first quarter of 2022.
  • The Company currently anticipates completing dosing in the second half of 2022 and reporting topline results within two months of study completion.
  • Research and development expenses in the first quarter of 2022 were $2.4 million, compared to $2.9 million in the prior year period.
  • General and administrative expenses were $2.1 million during the first quarter of 2022 versus $1.7 million in the comparable quarter last year.

CūtisCare Launches Second Annual Hyperbaric Aware™ National Campaign To Elevate Awareness Of Hyperbaric Oxygen Therapy

Retrieved on: 
星期一, 五月 2, 2022
Diabetes, Medicare, Centers for Medicare & Medicaid Services, Light, Culture, Underwater environment, Injury, Chronic radiation syndrome, Radiation, Physician, BOCA, Amputation, Patient, Infection, Blood, Ulcer, Center for Medicare and Medicaid Innovation, Cancer, Undersea and Hyperbaric Medical Society, Compliance, Hospital, Ethics, CMS, Center, Academic health science centre, Quality of life, HBOT, Awareness, Solution, Research, Growth, Pharmaceutical industry, Medical imaging

BOCA RATON, Fla., May 2, 2022 /PRNewswire/ -- CtisCare, a leader in wound care and hyperbaric management, launches its second annual Hyperbaric Aware national campaign to elevate awareness of hyperbaric oxygen therapy .

Key Points: 
  • BOCA RATON, Fla., May 2, 2022 /PRNewswire/ -- CtisCare, a leader in wound care and hyperbaric management, launches its second annual Hyperbaric Aware national campaign to elevate awareness of hyperbaric oxygen therapy .
  • Hyperbaric oxygen therapy is a treatment for wounds, infections, or injuries that have not responded to standard care.
  • Hyperbaric oxygen therapy (HBOT) is a proven treatment option for wounds, infections, or injuries that have not responded to standard treatment.
  • Throughout this month (and beyond), the Hyperbaric Aware campaign aims to promote hyperbaric oxygen therapy benefits, which will help people prolong lives, reduce amputations, and reduce the cost of care while improving quality of life.

Diffusion Pharmaceuticals Completes Dosing in Altitude Trial

Retrieved on: 
星期一, 四月 11, 2022
Company, Private Securities Litigation Reform Act, Risk, Undersea and Hyperbaric Medical Society, Particular, Hypoxia, NASDAQ, Trial of the century, Compliance, Diffusion, Blood gas tension, Physiology, VO2, Underwater environment, Food, Tissue, Oxygen, Industry, Exertion, U.S. Securities and Exchange Commission, Altitude, TSC, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Annual report, Volunteering, Pharmaceutical industry, Medical imaging, Nasdaq

CHARLOTTESVILLE, Va., April 11, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced the final participant has completed dosing in its Altitude Trial.

Key Points: 
  • CHARLOTTESVILLE, Va., April 11, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (Diffusion or the Company), a biopharmaceutical company developing novel therapies that enhance the bodys ability to deliver oxygen to areas where it is needed most, today announced the final participant has completed dosing in its Altitude Trial.
  • I would like to express our gratitude to the esteemed investigators and the participants in this clinical study, said Chris Galloway, M.D., Chief Medical Officer of Diffusion.
  • Topline, unblinded data from the Altitude Trial will be available within two months.
  • Diffusion Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapies that enhance the bodys ability to deliver oxygen to areas where it is needed most.

CūtisCare & Learn Look Locate Partner To Promote Healing After Radiation

Retrieved on: 
星期四, 三月 10, 2022
Community, Undersea and Hyperbaric Medical Society, Ischemia, Hyperbaric medicine, Physician, Compliance, OR, Research, Medicine, Academic health science centre, Education, Ethics, Culture, HBOT, Multimedia, Woman, Hospital, BOCA, Radiation, Patient, Breast cancer, STRN, Solution, Ulcer, Population, Legacy Emanuel Medical Center, CEO, Diagnosis, View, Underwater environment, Medical imaging

BOCA RATON, Fla., March 9, 2022 /PRNewswire/ -- CtisCare USA is partnering with Learn Look Locate through its Hyperbaric Aware initiative to help educate women and the breast cancer community about the life-changing benefits of Hyperbaric Oxygen Therapy (HBOT).

Key Points: 
  • BOCA RATON, Fla., March 9, 2022 /PRNewswire/ -- CtisCare USA is partnering with Learn Look Locate through its Hyperbaric Aware initiative to help educate women and the breast cancer community about the life-changing benefits of Hyperbaric Oxygen Therapy (HBOT).
  • To ensure our community has access to the latest research and insights, there are now information sections on both Learn Look Locate and Hyperbaric Aware highlighting healing after radiation through HBOT.
  • CtisCare offers hospitals and physician practices customized management solutions to begin providing next-level care for their patients.
  • Learn Look Locate was founded in 2018 as a global movement for support and education for breast cancer.

San Jose Mayor Sam Liccardo Honors O'Connor Hospital Wound Care Center for 25 Years of Exemplary Work

Retrieved on: 
星期三, 六月 26, 2019
Diving medicine, Oxygen, Medicine, Health, Undersea and Hyperbaric Medical Society, San Jose City Council, Hyperbaric medicine

Signed by San Jose Mayor Sam Liccardo, Vice Mayor Charles Jones, and all the members of the San Jose City Council, the commendation was formally presented by Councilmember Dev Davis to Dr. Polyxene Kokinos, Medical Director, and Dr. Bruce Lerman, one of the co-founders of the Wound Care Center.

Key Points: 
  • Signed by San Jose Mayor Sam Liccardo, Vice Mayor Charles Jones, and all the members of the San Jose City Council, the commendation was formally presented by Councilmember Dev Davis to Dr. Polyxene Kokinos, Medical Director, and Dr. Bruce Lerman, one of the co-founders of the Wound Care Center.
  • O'Connor Hospital Wound Care Center was founded 25 years ago by Dr. Bruce Lerman, Dr. Peter Schubart, and Dr. Jude Roussere, all of whom still play an active role.
  • To learn more about O'Connor Hospital Wound Care Clinic's advanced wound care programs, visit https://oconnor.verity.org/OCH/woundCare.php .
  • Founded in 1993, O'Connor Hospital Wound Care Clinic is the only Joint Commission Certified Wound Care Center and the only accredited Undersea and Hyperbaric Medical Society (UHMS) program in the SF Bay Area.